Kintara Therapeutics PE 2024

Ko dara Kintara Therapeutics?

Kintara Therapeutics Inc is a US-based biosciences company specializing in the development of cancer drugs and other clinical therapies. It was originally founded as DelMar Pharmaceuticals in 2008 before being renamed Kintara Therapeutics in 2019. The company focuses on developing drugs for the treatment of severe types of cancer such as glioblastoma, a particularly aggressive form of brain tumors. In addition, Kintara Therapeutics also develops clinical therapies for a broader range of indications, including breast cancer and lung cancer. Kintara Therapeutics has developed a proprietary technology platform called VAL-083, which is based on the effect of a chemical compound called dianhydrogalactitol (DAG). VAL-083 is being investigated as a potential treatment for various types of cancer, including those that have become resistant to other therapies. VAL-083 has received orphan drug designation status in the United States and Europe. This means that it is considered a promising new therapy for rare and serious diseases, allowing Kintara Therapeutics to have a faster approval process. In addition to the development of VAL-083, Kintara Therapeutics is also conducting a number of clinical trials on other drug candidates in its pipeline. This includes REM-001, a novel photoimmunotherapy drug for the treatment of cutaneous T-cell lymphomas. REM-001 is based on the use of light and a special type of antibodies to selectively destroy cancer cells. Another important area of business for Kintara Therapeutics is academic collaboration. The company works closely with academic institutions such as the Mayo Clinic, Duke University, and the University of California (San Francisco) to develop and test potential therapies. In addition, Kintara Therapeutics has also partnered with IQVIA, a leading provider of clinical study services, in order to achieve optimal results. In addition to the development and commercialization of cancer drugs, Kintara Therapeutics is also committed to responsible corporate governance. The company is dedicated to having a positive impact on patients, healthcare, and society as a whole through its products and business practices. Overall, Kintara Therapeutics has established a reputation as a reliable partner for the development of cancer therapies and other clinical therapies. The company has a strong portfolio of drug candidates and a broad base for collaborations to unleash its potential in healthcare. Kintara Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.